212 related articles for article (PubMed ID: 37239841)
1. Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice.
Inia JA; Stokman G; Morrison MC; Worms N; Verschuren L; Caspers MPM; Menke AL; Petitjean L; Chen L; Petitjean M; Jukema JW; Princen HMG; van den Hoek AM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239841
[TBL] [Abstract][Full Text] [Related]
2. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
4. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
6. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
7. A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice.
Zheng S; Yang W; Yao D; Tang S; Hou J; Chang X
Ann Med; 2022 Dec; 54(1):2233-2245. PubMed ID: 35950602
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
Aljobaily N; Krutsinger K; Viereckl MJ; Joly R; Menlove B; Cone B; Suppes A; Han Y
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615835
[TBL] [Abstract][Full Text] [Related]
9. Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr-/-.Leiden mice with manifest obesity-associated NASH.
Gart E; van Duyvenvoorde W; Caspers MPM; van Trigt N; Snabel J; Menke A; Keijer J; Salic K; Morrison MC; Kleemann R
FASEB J; 2022 Aug; 36(8):e22435. PubMed ID: 35830259
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
[TBL] [Abstract][Full Text] [Related]
13. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk.
van den Hoek AM; de Jong JCBC; Worms N; van Nieuwkoop A; Voskuilen M; Menke AL; Lek S; Caspers MPM; Verschuren L; Kleemann R
Metabolism; 2021 Nov; 124():154873. PubMed ID: 34478753
[TBL] [Abstract][Full Text] [Related]
14. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
[TBL] [Abstract][Full Text] [Related]
15. Heat-Inactivated
Morrison MC; Gart E; Duyvenvoorde WV; Snabel J; Nielsen MJ; Leeming DJ; Menke A; Kleemann R
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216439
[TBL] [Abstract][Full Text] [Related]
16. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis.
Hsieh YC; Wu PS; Lin YT; Huang YH; Hou MC; Lee KC; Lin HC
FASEB J; 2022 Oct; 36(10):e22526. PubMed ID: 36063123
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
[TBL] [Abstract][Full Text] [Related]
19. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice.
Morrison MC; Mulder P; Salic K; Verheij J; Liang W; van Duyvenvoorde W; Menke A; Kooistra T; Kleemann R; Wielinga PY
Int J Obes (Lond); 2016 Sep; 40(9):1416-23. PubMed ID: 27121255
[TBL] [Abstract][Full Text] [Related]
20. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
